Honorable Chairmen Rogers and Ranking Member Lowey, thank you for the opportunity to submit this testimony. I am Daniel Paul Perez, of Bedford, Massachusetts, President and CEO of the FSH Society, Inc. and an individual who has lived with facioscapulohumeral muscular dystrophy (FSHD) for 50 years. For hundreds of thousands of men, women, and children worldwide the major consequence of inheriting this form of muscular dystrophy is a lifelong progressive loss of all skeletal muscles. FSHD is a crippling and life shortening disease. No one is immune. It is both genetically and spontaneously transmitted to children. It can affect multiple generations and entire family constellations.

The National Institutes of Health (NIH) is the principal source of funding of research on Facioscapulohumeral Muscular Dystrophy (FSHD) currently at the $6 million level. Over many years, this Committee has supported the incremental growth in funding for FSHD research. I am pleased to report that this modest investment has produced huge scientific returns.

1. Congress has made a major difference in muscular dystrophy

I have testified many times before Congress. When I first testified, we did not know the mechanism of this disease. Now we do. When I first testified, we assumed that FSHD was a rare form of muscular dystrophy. Now we understand it to be one of the most prevalent forms of muscular dystrophy. Congress is responsible for this success, through its sustaining support of the National Institutes of Health (NIH), and the enactment of the Muscular Dystrophy CARE
Act. I am testifying in order to document this success and call on Congress to continue the momentum of discovery you have set in motion.

Congress enacted The Muscular Dystrophy Community Assistance, Research and Education Amendments of 2001 (the MD-CARE Act, Public Law 107-84) on December 18, 2001. It was reauthorized in 2008 and new efforts are underway to reauthorize the MD-CARE Act as it will expire in 2013. We are hopeful that this reauthorization bill will receive the same overwhelming bi-partisan support enjoyed in earlier enactments.

2. Quantum leaps in our understanding of FSHD have occurred in past three years

The past three years have seen remarkable contributions made by researchers funded by NIH.

- On August 19, 2010, American and Dutch researchers published a paper which dramatically expanded our understanding of the mechanism of FSHD. A front page story in the New York Times quoted the NIH Director Dr. Francis Collins saying, “If we were thinking of a collection of the genome’s greatest hits, this would go on the list.”

- Two months later, another paper was published that made a second critical advance in determining the cause of FSHD. The research shows that FSHD is caused by the inefficient suppression of a gene that may be normally expressed only in early development.

- On January 17, 2012, an international team of researchers based out of Seattle discovered a gene called DUX4 required to develop chromosome 4 linked FSHD.

- Six months later, another high profile paper produced by a Senator Paul A. Wellstone Cooperative Research Center of the NIH, used sufficiently “powered” large collections of genetically matched FSHD cell lines generated by the NIH center that are both
unique in scope and shared with all researchers worldwide, to improve on the Seattle
group’s finding by postulating that DUX4-fl expression is necessary but not sufficient
by itself for FSHD muscle pathology. This work was also supported by a NIH
cooperative research center grant mandated by MD CARE Act.

- On July 13, 2012, a team of international researchers from the United States,
  Netherlands and France identified mutations in a gene causing 80% of another form of
  FSHD. This paper furthers our understanding of the molecular pathophysiology of
  FSHD. This work too was supported in part by a program project grant from NIH.

I am proud to say that many of these researchers have started their efforts in FSHD with seed
funding from the FSH Society and have received continued support from the FSH Society, the
National Institutes of Health, and the Muscular Dystrophy Association and other partners. This
shows the power of the collaboration among funders, patient groups and researchers to advance
the search for cures and treatments.

3. Remarkable progress in FSHD research and the need to keep moving forward

Given the recent developments, there is a need to ramp up the preclinical enterprise and
build/organize infrastructure needed to conduct clinical trials. Our immediate priorities should
be to confirm the new hypotheses and targets. We need to be prepared for this new era in the
science of FSHD, by accelerating efforts in the following five areas:

1. Genetics / epigenetics
2. FSHD molecular networks
3. Clinical trial readiness
4. Model systems
5. Sharing

We would be pleased to provide the Committee with detailed information on each of these
areas. The pace of discovery and numbers of experts in the field of biological science and
clinical medicine working on FSHD are rapidly expanding. Many leading experts are now turning to work on FSHD not only because it is one of the most complicated and challenging problems seen in science, but because it represents the potential for great discoveries, insights into stem cells and transcriptional processes and new ways of treating human disease.

4. NIH Funding for Muscular Dystrophy

Mr. Chairman, these major advances in scientific understanding and epidemiological surveillance are not free. They come at a cost. Since Congress passed the MD CARE Act, research funding at NIH for muscular dystrophy has increased 4-fold. While FSHD research funding has increased 12-fold during this period, the level of funding is still exceedingly modest.

FSHD Research Dollars (in millions) & FSHD as a Percentage of Total NIH Muscular Dystrophy Funding

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All MD ($ millions)</td>
<td>$12.6</td>
<td>$21</td>
<td>$27.6</td>
<td>$39.1</td>
<td>$38.7</td>
<td>$39.5</td>
<td>$39.9</td>
<td>$47.2</td>
<td>$56</td>
<td>$83</td>
<td>$86</td>
<td>$75</td>
<td>$75</td>
</tr>
<tr>
<td>FSHD ($ millions)</td>
<td>$0.4</td>
<td>$0.5</td>
<td>$1.3</td>
<td>$1.5</td>
<td>$2.2</td>
<td>$2.0</td>
<td>$1.7</td>
<td>$3</td>
<td>$3</td>
<td>$5</td>
<td>$6</td>
<td>$6</td>
<td>$6</td>
</tr>
<tr>
<td>FSHD (% total MD)</td>
<td>3%</td>
<td>2%</td>
<td>5%</td>
<td>4%</td>
<td>6%</td>
<td>5%</td>
<td>4%</td>
<td>5%</td>
<td>5%</td>
<td>6%</td>
<td>7%</td>
<td>8%</td>
<td>8%</td>
</tr>
</tbody>
</table>

Despite the great success of the past two and a half years in the science of FSHD brought about by Congress we are concerned that the budget cuts required by the sequester are coming at a time when many of the FSHD research projects are ending. It is likely that new research projects will not be funded or existing programs will not be renewed. This is a perfect storm that could have devastating effects on FSHD research efforts. I served on the federal advisory committee MDCC for nine years until 2011. We have conveyed to the Executive Secretary of the MDCC our grave concern that the current portfolio of research on FSHD has a disproportionate number of FSHD grants near the end or in the last year of their grant cycles. While most are
competitively renewable this occurrence could not have happened at a worst time with sequestration making meat axe cuts across all federal agencies.

We request for FY2014, a doubling of the facioscapulohumeral muscular dystrophy (FSHD) research budget to $12 million dollars. This will allow an expansion of the U.S. DHHS NIH Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers, an increase in research awards, expansion of post-doctoral and clinical training fellowships, and a dedicated center to design and conduct clinical trials on FSHD.

We are aware of the great pressures on the federal budget, but cutting the NIH budget and research funding for FSHD at this time would be the wrong decision. We have come so far with such modest funding. This is not the time to lessen our endeavor. This is the time to fully and expeditiously exploit the advances for which the American taxpayer has paid.

Thank you for this opportunity to testify before your committee.

Footnotes:

7. 2012 FSH Society FSHD International Research Consortium, held November 6, 2012 co-sponsored by DHHS NIH NICHD Boston Biomedical Research Institute Senator Paul D. Wellstone MD CRC for FSHD. To read the expanded summary and recommendations of the group see: http://www.fshsociety.org/pages/sciConsortium.html